195 related articles for article (PubMed ID: 24999729)
1. Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).
Magnussen S; Rikardsen OG; Hadler-Olsen E; Uhlin-Hansen L; Steigen SE; Svineng G
PLoS One; 2014; 9(7):e101895. PubMed ID: 24999729
[TBL] [Abstract][Full Text] [Related]
2. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Bacchiocchi R; Rubini C; Pierpaoli E; Borghetti G; Procacci P; Nocini PF; Santarelli A; Rocchetti R; Ciavarella D; Lo Muzio L; Fazioli F
BMC Cancer; 2008 Aug; 8():220. PubMed ID: 18673553
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Nozaki S; Endo Y; Kawashiri S; Nakagawa K; Yamamoto E; Yonemura Y; Sasaki T
Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521
[TBL] [Abstract][Full Text] [Related]
6. Plectin as a prognostic marker in non-metastatic oral squamous cell carcinoma.
Rikardsen OG; Magnussen SN; Svineng G; Hadler-Olsen E; Uhlin-Hansen L; Steigen SE
BMC Oral Health; 2015 Aug; 15():98. PubMed ID: 26306491
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen Activation System in Rectal Adenocarcinoma.
Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Christensen A; Kiss K; Lelkaitis G; Juhl K; Persson M; Charabi BW; Mortensen J; Forman JL; Sørensen AL; Jensen DH; Kjaer A; von Buchwald C
BMC Cancer; 2017 Aug; 17(1):572. PubMed ID: 28841839
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Horch HH
Mund Kiefer Gesichtschir; 2004 May; 8(3):180-90. PubMed ID: 15138856
[TBL] [Abstract][Full Text] [Related]
10. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
11. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
12. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
13. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
14. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
16. Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression.
Ghosh S; Koblinski J; Johnson J; Liu Y; Ericsson A; Davis JW; Shi Z; Ravosa MJ; Crawford S; Frazier S; Stack MS
Mol Cancer Res; 2010 Feb; 8(2):145-58. PubMed ID: 20145038
[TBL] [Abstract][Full Text] [Related]
17. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Taubert H; Würl P; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Meye A; Eckert AW; Holzhausen HJ; Magdolen V; Kotzsch M
Br J Cancer; 2010 Feb; 102(4):731-7. PubMed ID: 20051950
[TBL] [Abstract][Full Text] [Related]
18. Sushi Repeat Containing Protein X-linked 2 Is a Downstream Signal of LEM Domain Containing 1 and Acts as a Tumor-Promoting Factor in Oral Squamous Cell Carcinoma.
Sasahira T; Kurihara-Shimomura M; Nishiguchi Y; Shimomura H; Kirita T
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455867
[TBL] [Abstract][Full Text] [Related]
19. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
20. Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas.
Shi Z; Liu Y; Johnson JJ; Stack MS
Mol Cell Biochem; 2011 Nov; 357(1-2):151-61. PubMed ID: 21630091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
